SecBot SecBot
SECBOTREPLAY Home › Report › INBX

INBX · $150M ATM equity offering

Inhibrx Biosciences, Inc. · S-3ASR filed Nov 13, 2026 at 16:25 ET

At the news

BEARISHIMPACT 5/10

S-3ASR filed Nov 13, 2026 at 16:25 ET

Inhibrx filed an automatic shelf registration (S-3ASR) and a prospectus supplement for an at-the-market (ATM) equity offering of up to $150M in common stock, with Stifel and LifeSci Capital as sales agents. The filing coincides with the same-day release of Q3 2026 results showing a net loss of $38.7M, cash of $199.5M, and $275M in outstanding debt, indicating the company needs capital to fund clinical development and potential commercialization of ozekibart ahead of a BLA filing.

  • S-3ASR filed November 13, 2026 for up to $150M in common stock via ATM offering
  • Sales agents: Stifel, Nicolaus & Company and LifeSci Capital; commission up to 3.0%
  • Q3 2026 net loss of $38.7M ($2.46/share) vs $35.3M ($2.28/share) in Q3 2025
  • Cash and cash equivalents of $199.5M as of September 30, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access